



Breaking through the Barricades: Immune Checkpoint Molecules and Immunotherapy in Cancer

Guest Editor:

Dr. Eva Andreuzzi

Department of Research and
Diagnosis, Division of Molecular
Oncology, Centro di Riferimento
Oncologico di Aviano (CRO)
IRCCS, Aviano, Italy

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editor

This Special Issue will focus on emerging trends in immune checkpoint molecules and immunotherapy in cancer. Although the use of PD-1/PD-L1 and CTLA-4 inhibitors yields unprecedented clinical effects, the role of ICIs in the modulation of the crosstalk between cancer cells and other tumor-associated cell types (e.g., immune and vascular cells) is another key feature that still has not been deeply investigated. The discovery of these mechanisms has the potential to give rise to the development of new therapeutic strategies, and to the development of new prognostic and predictive biomarkers.

This Special Issue invites submissions in any area relating to these themes. Possible topics within this scope include (but are not limited to) the following:

- Identification of novel immune checkpoints and inhibitors;
- Molecular mechanisms regulating immune checkpoint molecule expression;
- Mechanisms of resistance to ICIs;
- Strategies to improve the efficacy of ICIs;
- Impact of ICIs on tumor angiogenesis and lymphangiogenesis;
- Mechanisms of tumor cell invasion and metastatic dissemination;
- Evaluation of new biomarkers with predictive value for ICI therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)